silverback therapeutics is a biotechnology company that was founded in 2016. the company is based in seattle, wa and is funded by orbimed.
Company profile
Ticker
SPRY
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Silverback Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
ARS Pharmaceuticals Operations, Inc. • ARS Pharmaceuticals IRL, Limited ...
IRS number
811489190
SPRY stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
8-K
Regulation FD Disclosure
25 Sep 23
8-K
Other Events
20 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
10 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 60.53 mm | 60.53 mm | 60.53 mm | 60.53 mm | 60.53 mm | 60.53 mm |
Cash burn (monthly) | 19.50 mm | (no burn) | 5.99 mm | 6.06 mm | 4.25 mm | 5.20 mm |
Cash used (since last report) | 116.14 mm | n/a | 35.70 mm | 36.11 mm | 25.35 mm | 30.96 mm |
Cash remaining | -55.61 mm | n/a | 24.83 mm | 24.42 mm | 35.19 mm | 29.57 mm |
Runway (months of cash) | -2.9 | n/a | 4.1 | 4.0 | 8.3 | 5.7 |
Institutional ownership, Q3 2023
92.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 101 |
Opened positions | 23 |
Closed positions | 17 |
Increased positions | 38 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 251.06 bn |
Total shares | 89.67 mm |
Total puts | 408.40 k |
Total calls | 982.00 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Deerfield Management | 11.08 mm | $41.87 bn |
Flynn James E | 11.08 mm | $0.00 |
Pratik Shah Living Trust dated June 15, 2011 | 10.16 mm | $0.00 |
Ra Capital Management | 9.46 mm | $35.76 bn |
Orbimed Advisors | 9.24 mm | $34.93 bn |
Charles Schwab Trust | 4.25 mm | $16.05 bn |
SR One Capital Management | 4.01 mm | $15.17 bn |
BEN Franklin Resources | 3.87 mm | $14.62 bn |
BLK Blackrock | 2.57 mm | $9.70 bn |
K2 Principal Fund | 2.55 mm | $9.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Ra Capital Management | Common Stock | Buy | Acquire P | Yes | No | 9.79 | 505,954 | 4.95 mm | 9,958,073 |
26 Mar 24 | Ra Capital Management | Common Stock | Buy | Acquire P | Yes | No | 9.55 | 457,745 | 4.37 mm | 9,452,119 |
25 Mar 24 | Ra Capital Management | Common Stock | Buy | Acquire P | Yes | No | 9.06 | 437,600 | 3.96 mm | 8,994,374 |
25 Mar 24 | Sarina Tanimoto | Common Stock | Sell | Dispose S | Yes | Yes | 9.1236 | 47,632 | 434.58 k | 1,948,499 |
25 Mar 24 | Sarina Tanimoto | Common Stock | Sell | Dispose S | Yes | Yes | 9.1238 | 47,635 | 434.61 k | 1,697,447 |
25 Mar 24 | Richard E Lowenthal | Common Stock | Sell | Dispose S | Yes | Yes | 9.1236 | 47,632 | 434.58 k | 1,948,499 |
25 Mar 24 | Richard E Lowenthal | Common Stock | Sell | Dispose S | Yes | Yes | 9.1238 | 47,635 | 434.61 k | 1,697,447 |
22 Mar 24 | Sarina Tanimoto | Common Stock | Sell | Dispose S | Yes | Yes | 9.0132 | 1,326 | 11.95 k | 1,996,131 |
22 Mar 24 | Sarina Tanimoto | Common Stock | Sell | Dispose S | Yes | Yes | 9.0298 | 1,017 | 9.18 k | 1,745,082 |
22 Mar 24 | Richard E Lowenthal | Common Stock | Sell | Dispose S | Yes | Yes | 9.0132 | 1,326 | 11.95 k | 1,996,131 |
News
Top 5 Health Care Stocks That May Plunge In March
28 Mar 24
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
26 Mar 24
CORRECTION: On Thursday March 21, 2024 ARS Pharmaceuticals Reported Q4 EPS $(0.07) Beats $(0.14) Estimate
22 Mar 24
ARS Pharmaceuticals Q4 2023 GAAP EPS $(0.57) Misses $(0.14) Estimate
21 Mar 24
Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $19 Price Target
11 Mar 24
Press releases
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 24
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
7 Mar 24
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
6 Mar 24
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
26 Feb 24
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
22 Feb 24